An observational study in Total Joint Arthroplasty and Periprosthetic Joint Infections, sponsored by University of Utah. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by University of Utah · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 36th largest by planned enrollment of the 50 observational ones that give a count, is one of 5 that started in 2018, is one of 50 observational ones, reaches primary completion later than 27 of the 45 other live ones, and was the 55th registered.
242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.
Browse Genetic Predisposition to Disease studies →37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:
University of Missouri-Columbia · Sites in United States
Ages 45–65 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 45–74 · Women only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Women only
Christopher Reilly · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 500 across 154 observational studies indexed under Genetic Predisposition to Disease.
Median enrollment 225 across the 37 interventional studies, 560 across the 50 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 87 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 2 studies filed under Genetic Predisposition to Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Genetic Predisposition to Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05205356Boston Children's HospitalVIGOR: Virtual Genome Center for Infant Health | 2026-12-31 |
| NCT05020574University of California, San FranciscoMicrobiome and Association With Implant Infections | 2026-12-31 |
| NCT06962059Abramson Cancer Center at Penn MedicineHealthy Volunteers Study | 2027-01-15 |
| NCT06450171Dana-Farber Cancer InstituteEvaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study | 2027-01-31 |
| NCT05161169Brigham and Women's HospitalImplementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators primary objective is to identify genetic factors that may increase the risk of patients developing a periprosthetic joint infections (PJI) following total joint arthroplasty (TJA). The investigators hope that by identifying genetic predispositions we will be able to provide patient specific care pathways to prevent or minimize the risk for PJI.
Surgical site infections (SSI), and more specifically periprosthetic joint infections (PJI), have plagued the orthopaedic surgeon since the introduction of total joint arthroplasty (TJA) procedures of the hip or knee in the mid twentieth century. It is estimated that the economic burden of PJI in the United States will approach 1.62 billion USD by 2020. Though methods of infection control have improved, the rate of PJI appears to have plateaued in the last several decades. Early rates of PJI in the first two decades of THA have been reported between 1 - 9%. Since the 1980's studies have reported rates between 1% - 3%. It has been suggested that as orthopaedic surgeons, doctors should not be satisfied with deep infection rates greater than 1%. Therefore, more must be done in order to prevent, or diminish the frequency, of PJI and its devastating effects on this patient population.
In hopes of allowing for early targeted prevention in potentially high-risk patients, risk calculators have been developed to identify patients at greater risk for developing infection following TJA. However, some investigators suggest that these scoring systems may not be ready for primetime use. Thus, further research is needed to improve the ability to accurately identify individuals at high risk for infection. Unfortunately, the ability to perform large scale longitudinal cohort studies needed to create and test these risk calculators isn't feasible. Thus, other methods of early identification are needed.
Genetic susceptibility testing for identifying patients at risk for disease is becoming more popular and may be a means by which patients at high-risk for PJI can be identified. A recent dermatological study on genetic risk factors for infection suggest that host attributes may play a role in the ability of the individual to be infected. When evaluating the risk of subsequent different site infection in patients with multiple TJA's, investigators suggest that some patients may be at greater risk for infection due to possible subclinical immune deficiencies. In 2013, one investigator reported familial susceptibility to surgical site infections (SSI), including but not isolated to PJI, through a large population based study. Further, a recent publication from this investigating institution demonstrated familial clustering in patients who suffered a PJI, showing an increased risk of PJI following TJA in relatives of patients who have experienced PJI. These families demonstrated infection rates of 9 - 17%. After performing a systematic review on the genetic susceptibility to PJI, the investigators concluded that though evidence exists supporting a genetic role in PJI, no definitive conclusions can be made given the relatively small amount of data available in the existing literature. The investigators further emphasize the need for prospective studies to validate previous findings and the relationship between genetic factors and PJI.
Given the evidence in the literature, the investigators hypothesize that a large familial study will provide greater evidence of a genetic susceptibility. The results of this study could validate previous research with smaller sample sizes and allow for early identification of high-risk patients via genetic susceptibility testing.
Family members (affected and unaffected) with an increased incidence of TJI with PJI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Recruitment of families with an increased incidence of TJI with PJI.
Genetic: Blood Draw or Saliva/Cheek Cell Sample:
Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
Also known as: Genetic sample
Genotyping
Samples will undergo genetic testing to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
Time frame: DNA extraction and analysis will be performed immediately after collection of blood draw or saliva/cheek cell sample by a certified core lab
Started Mar 2018 (actual). Primary completion is estimated for Mar 2029, 132 months after the start.
Of 80 non-industry observational studies under Genetic Predisposition to Disease, half reached primary completion within 96 months of starting (the median), counting those still running; a quarter within 52. This study's planned 132 months is above that.
Counting every sponsor, half of 82 studies reached it within 96 months; a quarter within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Mar 2028 → Mar 2029 and completion Mar 2028 → Mar 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genetic Predisposition to Disease →